1. Introduction

Dialysis consumables are essential inputs used in haemodialysis and peritoneal dialysis. They include bloodline tubing sets, dialysers, dialysis concentrates, catheters, needles, dialysis solutions, filters, cartridges, connectors, disinfectants and other single-use products.

Competition concerns can arise because dialysis treatment often involves highly specialised products, regulatory approvals, technical compatibility, recurring purchases, hospital procurement systems, and significant switching costs. In some segments, a manufacturer of dialysis machines may also supply compatible consumables, creating opportunities for tying, bundling or foreclosure.

The most directly relevant competition-law authorities include cases involving Fresenius, NxStage, dialysis concentrates, bloodline tubing and dialysis-related pharmaceuticals, together with broader medical-device and healthcare procurement precedents.

2. Relevant Markets

Competition authorities may define several distinct markets depending upon the product and competitive conditions.

A. Product markets

Possible markets include:

• haemodialysis bloodline tubing;
• dialysers/artificial kidneys;
• dialysis concentrates;
• peritoneal dialysis solutions;
• dialysis needles and catheters;
• dialysis machine-compatible cartridges;
• dialysis filters;
• dialysis-related pharmaceuticals;
• sterilisation and disinfection products.

A particularly important issue is whether products compatible with a particular dialysis machine constitute a separate relevant market.

For example, in the Fresenius/NxStage transaction, the FTC identified a market for bloodline tubing sets compatible with open-architecture haemodialysis machines. The FTC alleged that Fresenius and NxStage were two of only three significant suppliers in that market.

B. Geographic market

The geographic market may be:

• national;
• regional;
• local;
• hospital-specific; or
• procurement-contract-specific.

Importation, regulatory approvals, transportation costs, tender requirements and hospital purchasing practices may affect the geographic market.

3. Major Competition Concerns

3.1 Market concentration

A small number of manufacturers may supply critical dialysis consumables.

High concentration can create risks of:

• unilateral price increases;
• reduced innovation;
• supply restrictions;
• coordinated conduct;
• exclusion of smaller suppliers;
• dependence on a single manufacturer.

This issue was particularly visible in the Fresenius/NxStage transaction involving bloodline tubing.

3.2 Mergers and acquisitions

A merger between competing dialysis-consumable manufacturers may eliminate an important source of competition.

Competition authorities may examine:

1. number of remaining suppliers;
2. market shares;
3. closeness of competition;
4. product compatibility;
5. hospital switching possibilities;
6. entry barriers;
7. procurement contracts;
8. manufacturing capacity; and
9. whether alternative products are genuinely substitutable.

Fresenius Medical Care / NxStage

The FTC challenged Fresenius's proposed acquisition of NxStage because of concerns relating to bloodline tubing sets used in haemodialysis. The settlement required divestiture of NxStage's bloodline tubing assets to B. Braun.

This is one of the most directly relevant precedents for dialysis consumables.

4. Compatibility and Lock-In

Dialysis machines and consumables can create a systems-market problem.

A manufacturer may design:

Machine → proprietary cartridge → proprietary tubing → proprietary filter → proprietary software.

If competing consumables cannot practically be used with the machine, the manufacturer may acquire significant aftermarket power.

Competition concerns become stronger where:

• compatibility information is withheld;
• interfaces are proprietary;
• warranties are conditioned on using branded consumables;
• software prevents third-party products from operating;
• hospitals face significant switching costs.

Thus, a market apparently containing several manufacturers may function competitively differently if each machine ecosystem has its own captive consumables market.

5. Tying and Bundling

A dominant dialysis-machine manufacturer might condition the purchase or use of a machine upon purchasing consumables from the same manufacturer.

For example:

Dialysis machine + mandatory branded dialyser + branded tubing + branded cartridge

could potentially raise concerns under rules governing tying or bundled sales.

The relevant questions include:

• Does the supplier possess substantial market power in the tying product?
• Are the machine and consumable separate products?
• Is purchase of the consumable effectively compulsory?
• Are alternative consumables technically available?
• Does the arrangement foreclose rival suppliers?
• Are there legitimate safety or quality justifications?

The broader medical-device jurisprudence recognises that tying and exclusive-dealing theories can become relevant where a manufacturer controls a critical equipment platform.

6. Exclusive Dealing

Manufacturers may enter contracts with hospitals, dialysis chains or distributors requiring them to purchase dialysis consumables exclusively from one supplier.

Exclusive arrangements can produce legitimate efficiencies, such as:

• guaranteed supply;
• volume discounts;
• quality control;
• technical support;
• inventory management.

However, they may become problematic if a dominant supplier uses them to foreclose competing manufacturers.

Relevant factors include:

• duration of exclusivity;
• percentage of demand covered;
• market share of the supplier;
• availability of alternative purchasers;
• ability of rivals to achieve minimum efficient scale;
• ease of switching.

7. Loyalty Rebates and Volume Discounts

Dialysis consumables are purchased repeatedly. Consequently, suppliers may offer:

• volume rebates;
• loyalty discounts;
• bundled rebates;
• annual procurement discounts;
• target-based rebates.

These can benefit hospitals through lower prices but may raise competition concerns where a dominant supplier structures rebates so that hospitals have strong economic incentives to purchase nearly all requirements from it.

For example:

70% purchase → 3% rebate
90% purchase → 12% rebate
100% purchase → 20% rebate

The competitive assessment depends on the structure and foreclosure effect rather than merely the existence of a discount.

8. Group Purchasing Organisations and Hospital Procurement

Hospitals frequently purchase consumables through:

• tenders;
• group purchasing organisations;
• framework agreements;
• long-term supply agreements.

Large procurement organisations can generate substantial buyer power and lower prices.

However, competition concerns can arise where procurement arrangements:

• exclude new suppliers;
• use discriminatory qualification requirements;
• impose excessive compliance requirements;
• aggregate too much demand;
• require broad exclusivity;
• favour incumbent suppliers without objective justification.

The modern relevance of this issue is illustrated by Endure Industries v. Vizient, concerning a supplier of disposable medical supplies and a large healthcare group purchasing organisation. The Fifth Circuit addressed alleged exclusionary conduct and the importance of properly defining the relevant market.

9. Excessive Pricing

A dominant supplier of an essential dialysis consumable may potentially face allegations of excessive pricing.

The analysis generally requires consideration of:

• production costs;
• economic value;
• comparable prices;
• prices in other geographic markets;
• innovation and quality;
• regulatory costs;
• procurement discounts;
• bargaining power of hospitals.

In India, the CCI's healthcare jurisprudence has specifically considered whether medicines, medical devices and consumables supplied to hospital in-patients constitute separate secondary markets or part of a broader healthcare-services market. The Schott Glass India / hospital healthcare-market litigation illustrates the complexity of defining markets for hospital consumables and assessing alleged excessive pricing.

10. Refusal to Supply

A dominant manufacturer could potentially restrict supply to:

• competing dialysis clinics;
• independent distributors;
• hospitals dealing with rival manufacturers;
• third-party service providers.

A refusal to supply is not automatically unlawful. Competition analysis may depend on:

• dominance;
• indispensability of the product;
• existence of alternatives;
• discriminatory treatment;
• history of supplying the customer;
• effect on downstream competition;
• legitimate business justification.

11. Discrimination Between Hospitals or Distributors

A dominant supplier may provide different:

• prices;
• rebates;
• delivery terms;
• credit terms;
• warranties;
• technical support

to similarly situated buyers.

Differential treatment may be commercially legitimate, particularly where purchasing volumes differ. But discriminatory treatment may become problematic where it is designed to disadvantage downstream competitors or particular distributors.

12. Interoperability and Standards

Dialysis consumables often need to satisfy strict technical and safety requirements.

Manufacturers can legitimately impose:

• quality specifications;
• sterilisation requirements;
• compatibility requirements;
• regulatory certification;
• safety testing.

However, technical standards can also be manipulated to exclude competitors.

Competition authorities may therefore distinguish between:

genuine safety requirements

and

artificial technical barriers to entry.

This distinction is especially important where a manufacturer controls both the dialysis equipment and the consumable ecosystem.

13. Intellectual Property and Patents

Dialysis consumables may be protected by:

• patents;
• designs;
• trademarks;
• proprietary interfaces;
• manufacturing know-how.

IP rights are legitimate, but competition concerns can arise through:

• sham exclusion strategies;
• discriminatory licensing;
• refusal to license essential technology;
• patent settlements;
• tying IP licences to unrelated products;
• excessive restrictions on interoperability.

The existence of a patent alone does not establish competition-law liability.

14. Distribution Restrictions

Manufacturers may appoint:

• exclusive distributors;
• regional distributors;
• hospital-specific distributors.

Potential concerns include:

• territorial allocation;
• customer allocation;
• resale-price restrictions;
• restrictions preventing parallel distribution;
• distributor exclusivity;
• market sharing.

Where several manufacturers coordinate their distributors or divide hospitals or territories, the conduct may raise much more serious cartel concerns.

15. Cartel Risks

Dialysis consumables can be particularly vulnerable to procurement-related coordination because products are frequently purchased through tenders.

Potential cartel conduct includes:

• bid rotation;
• bid suppression;
• market allocation;
• price fixing;
• customer allocation;
• exchange of future pricing information.

For example, competing manufacturers might secretly agree:

Manufacturer A wins Hospital X;
Manufacturer B wins Hospital Y;
Manufacturer C wins Hospital Z.

Such conduct can eliminate the competitive process even when several bids technically exist.

16. Case Laws

1. Fresenius AG / Fresenius USA – FTC (1996)

This is a particularly important dialysis-consumables merger precedent.

The FTC challenged Fresenius's acquisition of National Medical Care because the transaction would combine significant producers of haemodialysis concentrate, an essential chemical input used in dialysis treatment.

The FTC's order required divestiture of a haemodialysis concentrate plant.

Principle

A merger involving an apparently specialised medical input can raise horizontal-merger concerns where the transaction substantially reduces the number of independent suppliers.

2. Fresenius Medical Care / NxStage – FTC (2019)

The FTC required divestiture of NxStage's bloodline tubing-set business following Fresenius's proposed acquisition of NxStage.

The FTC alleged that the parties were two of only three significant suppliers of bloodline tubing sets compatible with open-architecture haemodialysis machines.

Principle

A narrow product market can exist for compatible dialysis consumables, even where broader medical-device markets contain additional products.

3. Fresenius Medical Care / Daiichi Sankyo – FTC (2008)

Fresenius sought to acquire an exclusive licence concerning the manufacture and supply of Venofer, an intravenous iron preparation used substantially in dialysis patients.

The FTC identified concerns arising from Fresenius's position as a major dialysis-clinic operator and the possibility that the arrangement could allow internal costs to be artificially increased.

The consent order imposed restrictions concerning the reporting of Venofer prices.

Principle

Vertical relationships between a healthcare provider and a supplier of products used in that provider's downstream operations can generate self-dealing and vertical foreclosure concerns.

4. Fresenius Medical Care / Liberty Dialysis – FTC (2017)

Although primarily concerning dialysis services rather than consumables, this case is important because it demonstrates the competitive significance of concentration throughout the dialysis supply chain.

The FTC required Fresenius to sell 60 outpatient dialysis clinics in 43 local markets following its acquisition of Liberty Dialysis.

Principle

Competition authorities may examine dialysis markets locally because competitive conditions can vary substantially between geographic areas.

5. Fresenius / American Renal Associates – FTC (2007)

The FTC challenged an arrangement under which American Renal Associates agreed to pay Fresenius to close dialysis clinics located near competing ARA facilities.

The FTC treated the arrangement as an unlawful restraint because it removed existing competition.

Principle

Agreements involving payment to a competitor to exit a market can constitute serious anticompetitive conduct. The principle is relevant to dialysis consumables where manufacturers or distributors might attempt to eliminate rival supply channels.

6. DaVita / Total Renal Care – FTC (2022)

The FTC challenged DaVita's acquisition of dialysis clinics operated by the University of Utah Health because of concerns about reduced competition in outpatient dialysis services in the Provo, Utah market.

The proposed order required divestitures and imposed restrictions on certain contractual practices.

Principle

Dialysis-related competition can require market-specific analysis, particularly where a small number of suppliers or providers serve a concentrated local market.

7. M&M Medical Supplies & Service Co. v. Pleasant Valley Hospital, 981 F.2d 160 (4th Cir. 1993)

This case concerned alleged exclusionary conduct involving hospital-related medical equipment supply.

The Fourth Circuit considered whether the hospital had used monopoly power to foreclose competition and discussed earlier cases involving hospitals, exclusive dealing and restrictions on competing medical-equipment suppliers.

Principle

Hospital purchasing and access arrangements can have antitrust significance where they are used to exclude competing suppliers, although exclusionary effect and market power must be established.

8. Endure Industries v. Vizient – Fifth Circuit (2026)

Endure, a supplier of disposable medical products, challenged the practices of Vizient, a major healthcare group purchasing organisation.

The case concerned alleged monopolisation, exclusive dealing and vertical rebate arrangements in markets for disposable medical supplies. The court emphasised the importance of establishing a legally sufficient relevant market.

Principle

In healthcare procurement cases, an antitrust claimant must carefully establish the relevant product and geographic market before exclusionary theories can succeed.

17. Indian Competition-Law Perspective

Under the Competition Act, 2002, dialysis-consumable issues may potentially arise under:

Section 3

Prohibits agreements causing or likely to cause an appreciable adverse effect on competition.

Potential examples:

• price fixing;
• tender collusion;
• market allocation;
• distributor restrictions;
• exclusive supply arrangements.

Section 4

Deals with abuse of dominant position.

Potential issues include:

• unfair or discriminatory pricing;
• discriminatory conditions;
• denial of market access;
• tying;
• limiting production or technical development;
• leveraging dominance from dialysis machines into consumables.

Sections 5 and 6

These provisions become relevant where a merger or acquisition involves competing manufacturers or suppliers of dialysis consumables.

18. Key Competition-Law Tests

19. Special Importance of the Aftermarket

The aftermarket theory is particularly important for dialysis consumables.

Suppose:

Primary market: dialysis machine

Secondary market: compatible bloodlines, cartridges, filters and other consumables.

If a hospital buys a dialysis machine after receiving representations that multiple compatible consumables will remain available, the manufacturer may have limited ability to exploit the aftermarket.

Conversely, if the manufacturer controls compatibility and switching is expensive, the hospital may become effectively captive.

The competition assessment therefore needs to consider:

1. switching costs;
2. information available at the time of machine purchase;
3. availability of alternative consumables;
4. contractual restrictions;
5. technical interoperability;
6. expected life of the machine;
7. proportion of hospitals using the installed base;
8. ability of competing consumable manufacturers to enter.

20. Conclusion

Competition concerns in dialysis consumables are unusually significant because these products occupy the intersection of healthcare, specialised manufacturing, recurring procurement and equipment compatibility.

The most important competition issues are:

• horizontal concentration among manufacturers;
• mergers involving dialysis consumables;
• machine-consumable tying;
• proprietary compatibility;
• exclusive supply arrangements;
• loyalty rebates and bundling;
• hospital and GPO procurement;
• discriminatory pricing;
• refusal to supply;
• tender collusion;
• excessive pricing; and
• leveraging of dominance from dialysis equipment into consumables.

The Fresenius/NxStage bloodline tubing case is particularly instructive because it demonstrates that competition authorities may identify a narrowly defined market for compatible dialysis consumables, rather than treating all medical consumables as one broad market. The Fresenius haemodialysis-concentrate case similarly demonstrates that specialised dialysis inputs can constitute an independent competitive concern in merger review.